A Phase i dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 331-339

  Mayer, Erica L ^a   Scheulen, M E ^b   Beckman, J ^c   Richly, H ^b   Duarte, A ^d   Cotreau, M M ^d   Strahs, A L ^d   Agarwal, S ^d   Steelman, L ^d   Winer, E P ^a   Dickler, M N ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d AVEO ONCOLOGY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Metastatic breast cancer; Paclitaxel; Tivozanib; VEGFR inhibitor

Indexed keywords

PACLITAXEL; TIVOZANIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BACKACHE; BREAST METASTASIS; CAVA VEIN OBSTRUCTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; FEVER; FLATULENCE; HAND FOOT SYNDROME; HEADACHE; HEART PALPITATION; HIP FRACTURE; HUMAN; HYPERTENSION; LEUKOPENIA; LUMBAR VERTEBRAL FRACTURE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SPINE FRACTURE; STOMATITIS; SUPERIOR VENA CAVA OCCLUSION; VOMITING; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLASSIFICATION; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84881479859     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2632-9     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
2. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
3. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 29:669-676
4. Nakamura K, Taguchi E, Miura T, et al. (2006) KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 66:9134-9142
5. Eskens FA, de Jonge MJ, Bhargava P, et al. (2011) Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res 17:7156-7163
6. Nosov DA, Esteves B, Lipatov ON, et al. (2012) Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 30:1678-1685
7. Motzer RJ, Nosov D, Eisen T, et al. (2012) Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 30:277s (abstract 4501)
8. Miller K, Wang M, Gralow J, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
9. Rugo H, Barry WT, Moreno-Aspitia A (2012) Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30(18 suppl):abstract CRA1002
10. O'Shaughnessy J, Miles D, Gray R, et al. (2010) A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28(15 suppl):abstract 1005
11. Robert NJ, Dieras V, Glaspy J, et al. (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260
12. Miles D, Chan A, Romieu G, et al. (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26(20 suppl):abstract LBA1011
13. Brufsky A, Bonarenko I, Smirnov V, et al. (2009) RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69(24 suppl):abstract 42
14. Baselga J, Segalla JG, Roche H, et al. (2012) Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 30:1484-1491
15. Shishehbor MH, Aviles RJ, Brennan ML, et al. (2003) Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289:1675-1680
16. Corretti MC, Anderson TJ, Benjamin EJ, et al. (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 239:257-265
17. Mross K, Hauns B, Haring B, et al. (1998) Clinical phase I study with one-hour paclitaxel infusion. Ann Oncol 9:569-572
18. Mross K, Haring B, Hollander N, et al. (2002) Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial. Onkologie 25:503-508
19. Wilhelm SM, Carter C, Tang L, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
20. Foulkes WD, Brunet JS, Stefansson IM, et al. (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830-835
21. Nalwoga H, Arnes JB, Stefansson IM, et al. (2011) Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Res Treat 130:1063-1071
22. Brufsky A, Valero V, Tiangco B, et al. (2011) Bevacizumab (BEV) plus second-line taxane (TAX) or other chemotherapy (CT) for triple-negative breast cancer (TNBC): subgroup analysis of RIBBON-2. J Clin Oncol 29(82 suppl):abstract 1010
23. von Minckwitz G, Eidtmann H, Rezai M, et al. (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299-309
24. Bear HD, Tang G, Rastogi P, et al. (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366:310-320
25. Cameron D, Brown J, Dent R, et al. (2012) Primary results of BEATRICE, a randomized Phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Res 272:abstract S6-5
26. Dowlati A, Gray R, Sandler AB, et al. (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407-1412
27. Miles DW, de Haas SL, Dirix LY, et al. (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108:1052-1060
28. Gianni L, Romieu GH, Lichinitser M, et al. (2013) AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31:1719-1725
29. Schneider BP, Wang M, Radovich M, et al. (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678
30. Bertolini F, Shaked Y, Mancuso P, et al. (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845
31. Dahlberg SE, Sandler AB, Brahmer JR, et al. (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949-954
32. Rini BI, Cohen DP, Lu DR, et al. (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773
33. Goodwin R, Seymour L, Ding K, et al. (2009) Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: a randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer. J Clin Oncol 27(152 suppl):abstract 3527
34. O'Connor JP, Jackson A, Parker GJ, et al. (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189-195
35. Gatza ML, Kung HN, Blackwell KL, et al. (2011) Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res 13:abstract R62
36. Jubb AM, Miller KD, Rugo HS, et al. (2011) Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 17:372-381
37. Jin ZG, Ueba H, Tanimoto T, et al. (2003) Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 93:354-363
38. Mayer EL, Dallabrida SM, Rupnick MA, et al. (2011) Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 58:85-92